Glanvac 6 Vaccine (Canada)
This treatment applies to the following species:Clostridium Chauvoei-Novyi Type B-Perfringens Type D-Septicum-Tetani-Corynebacterium Pseudotuberculosis (Ovis) Bacterin-Toxoid
For use as an aid in prevention of caseous lymphadenitis (CLA or cheesy gland), enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg like disease) and blackleg in sheep and lambs and swelled head in rams.
Caseous lymphadenitis is a chronic disease of sheep. It is characterized by abscesses, containing a cheese-like green pus, in the superficial and internal lymph nodes (glands) and lungs. The disease is caused by Corynebacterium pseudotuberculosis (ovis) which gains entry through breaks or abrasions of the skin or mucous membranes. The disease is spread when superficial abscesses burst during handling or shearing with consequent contamination of the shearing floor, holding yards, dips and shearing tools. In a moist environment, the bacteria are able to survive for up to 8 months. It has been implicated as a cause of ill-thrift in ewes. Prevalence increases with age. Clean properties may become infected by the introduction of an infected animal.
Black disease occurs as a sequel to liver fluke infestation and can result in death. The use of Glanvac 6 as an aid in prevention of black disease does not protect against disease associated with liver fluke infection.
Directions For Use
For use in healthy sheep.
It is important that the vaccine is kept properly mixed before and during use.
Primary vaccination: Shake well and administer 1 mL subcutaneously high on the neck, behind the ear, followed by a second 1-mL dose 4 to 6 weeks later.
Revaccination: Annual revaccination with a single 1-mL dose is recommended. Booster doses typically confer lifelong immunity against tetanus, blackleg and malignant oedema. Lifelong immunity is not established against enterotoxaemia (pulpy kidney), black disease or caseous lymphadenitis.
Immunity to Clostridial diseases is established approximately 10 days following initial vaccination. The second dose, given four to six weeks after the first, should ensure a high level of immunity against these diseases. Immunity against caseous lymphadenitis develops within two weeks of administration of the second dose. To achieve maximum protection against caseous lymphadenitis, lambs should be vaccinated 2 weeks before probable exposure to infection. Annual revaccination should therefore be timed to provide protection at times of maximum exposure to the infectious agent e.g. for caseous lymphadenitis, before shearing and dipping; for enterotoxaemia prior to transfer to lush pasture or grain feeding.
General recommendations for vaccination:
In order to avoid carcass damage:
1. Use of new sterile needles is preferred. If using a non-sterile injection apparatus, it should be boiled in water for 10 minutes (or equivalent) before use. Avoid use of strong disinfectants on injection apparatus.
2. Maintain cleanliness at all times during vaccination. Great care must be taken to avoid contamination of the vaccine, needle and internal parts of the syringe by contact with unsterile surfaces or unwashed hands.
3. Keep needles sharp and clean. Replace frequently.
4. Use the shortest possible needle, not exceeding 5/8 inches in length.
5. Avoid injecting animals during wet weather or under dusty conditions. Animals should preferably be inoculated in temporary yards on clean grass, as shearing sheds and fixed mustering yards are likely to be heavily contaminated with clostridial spores and Corynebacterium pseudotuberculosis (ovis).
6. This product must only be injected under the skin (subcutaneously).
7. Inject high on the neck behind the ear, i.e. under the skin just behind and below the base of the ear. Do not inject at any other site. Young lambs may be vaccinated while being held. Older animals are most conveniently vaccinated while they are standing in a race.
8. Prior to vaccination, the proposed site of inoculation should be clean and free of debris. The site may be cleaned by swabbing with cotton-wool soaked in an antiseptic solution.
PRECAUTIONS
Store between 2°- 8°C. Keep refrigerated. Do not freeze. Protect from light.
Burn containers and all unused contents.
Do not vaccinate within 21 days before slaughter.
Contains thimerosal as preservative.
Localized swelling may develop at the site of injection and a firm nodular lump may persist for several months.
If anaphylaxis occurs following use, administer epinephrine or equivalent.
USER SAFETY INFORMATION
In the event of self-injection, seek medical attention immediately and take the package leaflet with you. Allow the wound to bleed freely and do not squeeze or interfere with the injection site to avoid spread of the vaccine. Clean the wound thoroughly with soap and water, and then keep it clean and dry. If pain persists after medical examination re-visit your health care professional.
Glanvac 6 is registered in packs of 100 mL (100 doses).
Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (800) 461-0917.
For veterinary use only.
Manufactured for: Zoetis Canada Inc., Kirkland, Quebec
Tel.: (800) 461-0917
40016721ZB
CPN: 1198542.1
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
Order Desk: | 800-663-8888 | |
Technical Services Canada: | 800-461-0917 | |
Technical Services USA: | 800-366-5288 | |
Website: | www.zoetis.ca |
THIS SERVICE AND DATA ARE PROVIDED "AS IS". Animalytix assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the Animalytix service and data. See the Terms of Use for further details. |
Copyright © 2024 Animalytix LLC. Updated: 2024-08-26